A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma

BACKGROUND: Smoldering multiple myeloma (SMM) is an indolent disease stage, considered to represent the transition phase from the premalignant MGUS (Monoclonal Gammopathy of Undetermined Significance) state towards symptomatic multiple myeloma (MM). Even though this diagnosis provides an opportunity...

Descripción completa

Detalles Bibliográficos
Autores principales: Wichert, Stina, Juliusson, Gunnar, Johansson, Åsa, Sonesson, Elisabeth, Teige, Ingrid, Wickenberg, Anna Teige, Frendeus, Björn, Korsgren, Magnus, Hansson, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291423/
https://www.ncbi.nlm.nih.gov/pubmed/28158311
http://dx.doi.org/10.1371/journal.pone.0171205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291423/
https://www.ncbi.nlm.nih.gov/pubmed/28158311
http://dx.doi.org/10.1371/journal.pone.0171205

Ejemplares similares